Yamada Kanae, Kato Naoyuki, Takagi Akimitsu, Koi Minoru, Hemmi Hiromichi
Department of Molecular Biology, Faculty of Medicine, Toho University, 5-21-16 Ohmori-Nishi, Ohta-ku, Tokyo, 143-8540, Japan.
Anal Bioanal Chem. 2005 Aug;382(7):1702-7. doi: 10.1007/s00216-005-3339-5. Epub 2005 Jun 16.
Platinum (Pt)-DNA adducts formed by the anti-tumor agent cisplatin are recognized by the DNA mismatch repair (MMR) system. To investigate the involvement of MMR proteins including hMLH1 in the removal of these adducts, we developed a mL-scale wet-digestion method for inductively coupled plasma mass spectrometry (ICP-MS). The detection limit was 0.01 ng mL(-1) Pt, which corresponded to 2 pg Pt/microg DNA when 10 microg of DNA was used. The mean relative errors were 5.4% or better for a dynamic range of 0.01-10 ng mL(-1) Pt. DNA (approximately 500 microg) had no matrix effect. To improve the accuracy, DNA preparations were treated with ribonuclease and the apparent reduction in the concentration of Pt was corrected using cellular DNA levels, which were determined with Hoechst 33258. No significant differences were observed, in terms of the formation of Pt-DNA adducts or their removal over 6 h, between hMLH1-deficient HCT116 cells, a human colorectal cancer cell line, and hMLH1-complemented HCT116+ch3 cells (n=5; P>0.05), indicating that the hMLH1-dependent DNA repair systems contribute to neither the formation nor the removal of the adducts at detectable levels. In addition, approximately 19% of the adducts were removed within 6 h in both cell lines. A time course analysis (~24 h) suggested that the removal of cisplatin-generated Pt-DNA adducts follows first-order kinetics (t(1/2)=32 h). The amount of Pt-DNA adduct formed by oxaliplatin in 1 h was 56% (ratio of means) of that generated by an equimolar concentration of cisplatin in HCT116. The proposed procedure could be useful for determining Pt-DNA adducts formed by Pt(II) complexes.
由抗肿瘤药物顺铂形成的铂(Pt)-DNA加合物可被DNA错配修复(MMR)系统识别。为了研究包括hMLH1在内的MMR蛋白在去除这些加合物中的作用,我们开发了一种用于电感耦合等离子体质谱(ICP-MS)的毫升规模湿消化方法。检测限为0.01 ng mL⁻¹ Pt,当使用10 μg DNA时,相当于2 pg Pt/μg DNA。在0.01 - 10 ng mL⁻¹ Pt的动态范围内,平均相对误差为5.4%或更低。DNA(约500 μg)没有基质效应。为提高准确性,DNA制剂用核糖核酸酶处理,并使用通过Hoechst 33258测定的细胞DNA水平校正Pt浓度的明显降低。在人结肠癌细胞系hMLH1缺陷的HCT116细胞和hMLH1互补的HCT116 + ch3细胞之间,就Pt-DNA加合物的形成或其在6小时内的去除而言,未观察到显著差异(n = 5;P>0.05),这表明hMLH1依赖的DNA修复系统在可检测水平上对加合物的形成或去除均无贡献。此外,在两个细胞系中,约19%的加合物在6小时内被去除。时间进程分析(约24小时)表明,顺铂生成的Pt-DNA加合物的去除遵循一级动力学(t₁/₂ = 32小时)。在HCT116中,奥沙利铂在1小时内形成的Pt-DNA加合物量是等摩尔浓度顺铂生成量的56%(均值比)。所提出的方法可用于测定由Pt(II)络合物形成的Pt-DNA加合物。